Acelyrin (NASDAQ: SLRN) Plummets on Disappointing HS Trial Results - TipRanks.com
Acelyrin's stock dropped after disappointing Phase 2b trial results for izokibep in treating Hidradenitis Suppurativa. Despite not meeting the primary endpoint, early HiSCR100 responses and dose-effect data support further evaluation. Analysts maintain a Strong Buy rating for SLRN.
Reference News
Acelyrin (NASDAQ: SLRN) Plummets on Disappointing HS Trial Results - TipRanks.com
Acelyrin's stock dropped after disappointing Phase 2b trial results for izokibep in treating Hidradenitis Suppurativa. Despite not meeting the primary endpoint, early HiSCR100 responses and dose-effect data support further evaluation. Analysts maintain a Strong Buy rating for SLRN.